Aevice Health vs Gameto
Side-by-side comparison of AI visibility scores, market position, and capabilities
Aevice Health raised $30M Series B in 2025 for its AI-powered wearable respiratory monitor that continuously tracks wheezing, coughing, and breathing abnormalities in asthma and COPD patients.
About
Aevice Health develops wearable respiratory monitoring technology that uses AI to analyze breath sounds captured continuously from a chest-worn device. The AeviceMD system detects wheezing, coughing, and abnormal breathing patterns in real time, enabling early warning of asthma attacks and COPD exacerbations before they require emergency care. The device transmits data to a smartphone app and clinical dashboard for remote monitoring by pulmonologists.
Gameto raised $70M Series B in 2024 for its stem cell technology that dramatically reduces IVF stimulation duration from 10 days to 2–3 days, making fertility treatment faster, cheaper, and less invasive.
About
Gameto is revolutionizing in vitro fertilization by engineering ovarian granulosa cells from stem cells that can mature patient eggs in the lab, eliminating the lengthy and hormone-intensive stimulation protocols required by conventional IVF. The company's Fertilo technology co-incubates patient egg cells with Gameto's lab-grown granulosa cells, achieving maturation in 2–3 days versus the 10+ days of hormone injections that characterize standard IVF stimulation.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.